Xolair (omalizumab) - Roche, Novartis
Tezspire (tezepelumab-ekko) - AstraZeneca, Amgen
Omlyclo (omalizumab-igec) - Celltrion
Nucala (mepolizumab) - GSK
Dupixent (dupilumab) - Sanofi, Regeneron
Tezepelumab (Tezspire) for nasal polyps. (PubMed, Med Lett Drugs Ther) - Oct 19, 2026 - No abstract available 
Journal • Immunology • Nasal Polyps • Otorhinolaryngology
http://www.ncbi.nlm.nih.gov/pubmed/42891993
 
Oct 19, 2026
 
Prev Next